Mumbai : Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, today announced its financial results for the first quarter ended June 30, 2026. For the first quarter of FY 2027, Glenmark’s consolidated revenue was
Rs. 40,185 million as against Rs. 32,644 million in the corresponding quarter last year, recording an overall growth of 23.1% YoY.
EBITDA was Rs. 8,048 million in the quarter ended June 30, 2026, registering 38.6% YoY growth and an EBITDA margin of 20.03%. Profit After Tax (PAT) for the quarter was Rs. 4,828 million, with a PAT margin of 11.8%.
Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. said, “We have started FY2027 with broad-based growth across our key markets, reflecting strong execution and the resilience of our business. India continued to outperform the market, North America delivered robust underlying growth driven by our first-to-market respiratory launches, and Emerging Markets sustained strong momentum, underscoring the strength of our diversified global business.
The results reinforce the direction of Glenmark’s next phase: strengthening our core businesses while expanding our differentiated specialty and innovation-led platforms. With RYALTRIS® continuing to grow globally, WINLEVI® gaining traction across Europe, and further progress across our oncology portfolio and IGI’s pipeline, we remain focused on disciplined execution, sustainable and profitable growth and creating long-term value.”
